Akero Therapeutics Inc (NASDAQ: AKRO) is 73.80% higher on its value in year-to-date trading and has touched a low of $17.86 and a high of $58.40 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The AKRO stock was last observed hovering at around $47.57 in the last trading session, with the day’s gains setting it 0.78%.
Currently trading at $48.35, the stock is 14.13% and 16.94% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.27 million and changing 1.64% at the moment leaves the stock 38.46% off its SMA200. AKRO registered 142.72% gain for a year compared to 6-month gain of 72.13%. The firm has a 50-day simple moving average (SMA 50) of $41.3445 and a 200-day simple moving average (SMA200) of $34.92025.
The stock witnessed a 25.58% loss in the last 1 month and extending the period to 3 months gives it a -4.41%, and is 27.64% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 10.43% over the week and 6.91% over the month.
Akero Therapeutics Inc (AKRO) has around 63 employees, a market worth around $3.85B and $0.00M in sales. Distance from 52-week low is 170.72% and -17.21% from its 52-week high. The company has generated returns on investments over the last 12 months (-24.21%).
The EPS is expected to shrink by -3.81% this year, but quarterly earnings will post 0.00% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
330.0 institutions hold shares in Akero Therapeutics Inc (AKRO), with institutional investors hold 110.80% of the company’s shares. The shares outstanding are 79.67M, and float is at 71.21M with Short Float at 9.53%. Institutions hold 109.28% of the Float.
The top institutional shareholder in the company is JANUS HENDERSON GROUP PLC with over 6.88 million shares valued at $161.28 million. The investor’s holdings represent 9.9425 of the AKRO Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 5.59 million shares valued at $131.06 million to account for 8.0778 of the shares outstanding. The other top investors are RTW INVESTMENTS, LP which holds 5.43 million shares representing 7.8542 and valued at over $127.43 million, while GENERAL ATLANTIC, L.P. holds 7.5679 of the shares totaling 5.23 million with a market value of $122.79 million.
Akero Therapeutics Inc (AKRO) Insider Activity
The most recent transaction is an insider sale by Yale Catriona, the company’s Chief Development Officer. SEC filings show that Yale Catriona sold 10,000 shares of the company’s common stock on May 15 ’25 at a price of $39.30 per share for a total of $0.39 million. Following the sale, the insider now owns 95034.0 shares.
Still, SEC filings show that on May 12 ’25, Cheng Andrew (President and CEO) disposed off 30,000 shares at an average price of $41.48 for $1.24 million. The insider now directly holds 594,324 shares of Akero Therapeutics Inc (AKRO).
